Given the potential pathogenetic differences between C9orf72 HREs with reduced and increased expression, the role of ATXN2 in C9orf72 HRE carriers warrants reevaluation in ALS patients lacking C9orf72 HREs [69]. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.